Figure 4

Dipyridamole reduces clinical and histological scores of EAE. (A) Clinical scores were reduced by 100 mg/kg dipyridamole (*P < 0.05) (n = 8 per group, mean ± SEM). (B) Hematoxylin and eosin and Luxol fast blue histological staining show multiple cellular infiltrates and demyelination in the vehicle-treated EAE group (top three panels at ×100, ×200 and ×400 original magnification, respectively, from left to right), which were reduced by dipyridamole (bottom three panels at ×100, ×200 and ×400 original magnification, respectively, from left to right). Arrows indicate the infiltrates that are highlighted in the higher-magnification photomicrographs. (C) Histological scores in dipyridamole-treated animals are reduced compared with vehicle-treated controls. (D) Clinical scores (represented as the sum of daily scores for each mouse over the entire experiment) correlated with histological scores (P < 0.001).